Drug Profile
Research programme: biosimilars - Momenta Pharmaceuticals
Alternative Names: M-511Latest Information Update: 18 Dec 2020
Price :
$50
*
At a glance
- Originator Momenta Pharmaceuticals
- Developer Momenta Pharmaceuticals; Viatris Inc
- Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies; Proteins
- Mechanism of Action CD80 antigen inhibitors; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Autoimmune disorders; Cancer; Inflammation
Most Recent Events
- 01 Oct 2020 Momenta Pharmaceuticals has been acquired by Johnson & Johnson
- 28 Oct 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in Europe (Parenteral)
- 28 Oct 2018 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)